Anakinra improves the central nervous system manifestations of neonatal-onset multisystem inflammatory disease, which is mediated by IL-1ß oversecretion. The cerebrospinal fluid (CSF) penetration of the IL-1 receptor antagonist anakinra was studied in rhesus monkeys after intravenous doses of 3 and 10 mg/kg. Drug exposure (area under concentration-time curve) in CSF was 0.28% of that in serum. The average CSF concentration at 3 mg/kg was 1.8 ng/mL, which is 30-fold higher than endogenous CSF levels of IL-1Ra. The CSF penetration was not dose-dependent, indicating that the CSF penetration was not saturated in the 3 to 10 mg/kg dose range.
Introduction
Interleukin-1 (IL-1), implicated in the pathogenesis of neonatalonset multisystem inflammatory disease (NOMID), mediates proinflammatory effects through binding to the IL-1 receptor which is present on many nucleated cells (Dinarello, 2004) . The recombinant IL-1 receptor antagonist, anakinra (IL-1Ra, Kineret™), improves the clinical and laboratory manifestations of NOMID in patients treated with 1-2 mg/kg daily by subcutaneous injection (Goldbach-Mansky et al., 2006; Lovell et al., 2005) . In addition to the disappearance of the cutaneous manifestations, an improvement in the central nervous system (CNS) manifestations was observed, including alleviation of headache, reduction in increased intracranial pressure, and decreased leptomeningeal and cochlear enhancement on MRI. The median (interquartile range) serum IL-1Ra concentration in patients with NOMID was 0.36 ng/mL (0.23-1.26 ng/mL) pretreatment and 43 ng/mL (8.8-200 ng/mL) after 3 months of anakinra. In CSF, IL-1Ra concentration was 0.21 ng/mL (0.077-0.35 ng/mL) and increased 5-fold on anakinra to 1.14 ng/mL (0.50-1.69 ng/mL) (Goldbach-Mansky et al., 2006) .
The clinical improvement in the CNS manifestations of NOMID and the increase in CSF IL-1Ra concentrations measured at a single time point post-treatment in children treated with anakinra prompted us to more fully characterize the CSF pharmacokinetics of anakinra in a non-human primate model, which is highly predictive of CNS pharmacology in humans (Bacher et al., 1994; McCully et al., 1990; Jacobs et al., 2005; Meany et al., 2007; Muscal et al., 2010) . Animals have chronically indwelling Ommaya reservoirs that permit serial atraumatic sampling of ventricular CSF to assess the time course of CSF drug concentrations after a systemic dose of drug. Drug exposure in CSF is compared to serum using the area under the concentrationtime curve (AUC) rather than single time point measurements. CSF drug penetration in this model is a surrogate for blood-brain barrier penetration (Fox et al., 2002) .
Materials and methods

Drug
Anakinra (100 mg/0.67 mL; Biovitrum, AB, Stockholm, Sweden) was purchased from commercial sources. Anakinra (17.3 kDa) differs from native human by the addition of a methionine at the amino terminus and the absence of glycosylation. Two dose levels (3 and 10 mg/kg) were studied. Each dose was diluted in normal saline to a final concentration of 25-50 mg/mL in 1-3 mL and administered as an intravenous (IV) bolus.
